Bristol-Myers Squibb vs Intel: Founders, CEOs and History
Bristol-Myers Squibb was founded in 1887 by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers and is led by Christopher Boerner. Intel was founded in 1968 by Robert Noyce, Gordon Moore and is led by Lip-Bu Tan.
Company facts
Bristol-Myers Squibb
- Founded
- 1887
- Headquarters
- Princeton, New Jersey
- Current CEO
- Christopher Boerner
- Employees
- 32,500
Intel
- Founded
- 1968
- Headquarters
- Santa Clara, California
- Current CEO
- Lip-Bu Tan
- Employees
- 85,100
Founders
Bristol-Myers Squibb
Edward Robinson Squibb
Squibb resigned his Navy post and opened a small laboratory in Brooklyn in 1858 to make pure ether, chloroform and other medicines.
William McLaren Bristol
In 1887 Bristol and Myers bought the Clinton Pharmaceutical Company of Clinton, New York, reportedly for about $5,000.
John Ripley Myers
Myers and Bristol bought the Clinton Pharmaceutical Company in Clinton, New York, in 1887 and renamed it Bristol, Myers and Company in 1898.
Intel
Robert Noyce
Intel possesses the most well-known founding story in the entire history of Silicon Valley, famously founded by the effective, rebellious engineers who essentially invented the fundamental architecture of the modern digital world.
Gordon Moore
Gordon Moore co-founded Intel and served as a key technical leader, CEO, and chairman during the company's formative decades. His most important contribution was turning transistor scaling into a corporate operating philosophy.
CEOs and their tenures
Bristol-Myers Squibb
- Charles A. Heimbold Jr.1994–2001
Chief Executive Officer
Serving as CEO from 1994 to 2001, he aggressively expanded the company's oncology portfolio, notably launching the blockbuster cancer drug Taxol, which drove massive revenue growth.
Source - Peter R. Dolan2001–2006
Chief Executive Officer
Dolan, who had run the consumer products and medical device divisions, succeeded Charles Heimbold in May 2001. His tenure included the ImClone partnership on the cancer drug Erbitux and a federal investigation into wholesaler inventory practices.
Source - James M. Cornelius2006–2010
Chief Executive Officer
Cornelius took over after Peter Dolan's removal in September 2006 and ran the company until May 2010.
Source - Lamberto Andreotti2010–2015
Chief Executive Officer
Andreotti, previously president and chief operating officer, became CEO on May 4, 2010.
Source - Giovanni Caforio2015–2023
Chief Executive Officer
Caforio, a physician, succeeded Lamberto Andreotti in May 2015. He led the $74 billion Celgene acquisition in 2019, the $13.1 billion MyoKardia deal in 2020 and the $4.1 billion Turning Point deal in 2022, and agreed the Mirati purchase in October 2023.
Source - Chris Boerner2023–present
Board Chair and Chief Executive Officer
Boerner became CEO in November 2023 and board chair on April 1, 2024, after serving as executive vice president, chief operating officer and CEO-designate from April 2023 and earlier as chief commercialization officer.
Source
Intel
- Andy Grove1987–1998
CEO
Grove turned Intel into the dominant PC processor supplier; revenue grew from about $1.9B in 1987 to over $26B in 1998. His book 'Only the Paranoid Survive' became a management classic.
Source - Pat Gelsinger2021–2024
CEO
Gelsinger rebuilt Intel's process roadmap toward 18A, but capital spending outpaced revenue. After a $18.8B net loss in 2024 and a dividend suspension, the board pushed him out in December 2024.
Source - Lip-Bu Tan2025–present
Chief Executive Officer
Tan reframed Intel around customer commitments and cost discipline rather than building capacity ahead of demand. By Q2 2026 Intel had beaten guidance for several straight quarters and posted its fastest revenue growth in more than 15 years.
Source
Timeline: Bristol-Myers Squibb and Intel side by side
1858Bristol-Myers Squibb
Edward Robinson Squibb opens his Brooklyn laboratory
Navy surgeon Edward Robinson Squibb started making pure ether and other medicines in Brooklyn. The laboratory burned down on Christmas Eve 1858 and reopened in 1859 after local doctors and surgeons contributed $2,100.
1887Bristol-Myers Squibb
Bristol and Myers buy the Clinton Pharmaceutical Company
Hamilton College graduates William McLaren Bristol and John Ripley Myers bought the Clinton Pharmaceutical Company of Clinton, New York, the business that became Bristol-Myers.
1898Bristol-Myers Squibb
Bristol, Myers and Company is named
The founders renamed the business Bristol, Myers and Company in May 1898. After Myers died in 1899 it became Bristol-Myers, which built national brands in Sal Hepatica and, from 1901, Ipana toothpaste.
1944Bristol-Myers Squibb
Penicillin at wartime scale
Squibb opened what was then the world's largest penicillin plant in New Brunswick, New Jersey. Bristol-Myers had bought Cheplin Biological Laboratories in East Syracuse, New York, in 1943 and converted it to penicillin for Allied forces.
1968Intel
Intel Founded
Robert Noyce and Gordon Moore founded Intel.
1971Intel
4004 Microprocessor
Intel introduced the 4004, one of the first commercial microprocessors.
1985Intel
386 Processor
Intel strengthened the x86 franchise that later dominated PCs.
1989Bristol-Myers Squibb
Bristol-Myers and Squibb merge
Bristol-Myers and Squibb combined to form Bristol-Myers Squibb, uniting a consumer and pharmaceutical company with a research-led drugmaker.
1993Intel
Pentium Processor Launched
Intel introduced the Pentium processor in 1993.
2006Bristol-Myers Squibb
CEO Peter Dolan removed over the Plavix deal
After an FBI raid in July 2006 over a patent settlement with generic maker Apotex on the blood thinner Plavix, the federal monitor urged the board to remove CEO Peter Dolan, who stepped down on September 12, 2006.
2006Intel
Core Architecture
Intel revived product leadership with the Core architecture.
2009Bristol-Myers Squibb
Medarex bought and Mead Johnson split off
BMS bought Medarex, gaining Yervoy and a share of what became Opdivo, and split off Mead Johnson Nutrition in an exchange offer, completing its shift to a specialty biopharmaceutical company.
2011Bristol-Myers Squibb
FDA approves Yervoy
Yervoy (ipilimumab) became the first drug shown to extend overall survival in advanced melanoma, opening BMS's immuno-oncology franchise.
2012Bristol-Myers Squibb
FDA approves Eliquis
The FDA approved Eliquis (apixaban), developed with Pfizer, in December 2012 for stroke prevention in non-valvular atrial fibrillation. It became BMS's largest product, with $14.4 billion of sales in 2025.
2014Bristol-Myers Squibb
FDA approves Opdivo
The FDA approved the PD-1 inhibitor Opdivo (nivolumab) in December 2014 for advanced melanoma. It reached $10.0 billion of sales in 2025.
2019Bristol-Myers Squibb
Celgene acquisition closes
BMS completed its $74 billion purchase of Celgene on November 20, 2019, adding Revlimid, Pomalyst, Reblozyl and CAR-T programs. Celgene sold Otezla to Amgen for $13.4 billion to win regulatory approval.
2020Bristol-Myers Squibb
MyoKardia deal and a GAAP loss
BMS bought MyoKardia for $13.1 billion, gaining mavacamten (Camzyos). The deal's $11.4 billion in-process R&D charge pushed 2020 to a net loss despite $42.5 billion of revenue.
2021Intel
IDM 2.0 Announced
Intel announced a strategy to expand manufacturing and foundry capabilities.
2021Intel
Pat Gelsinger Becomes CEO
Pat Gelsinger became Intel chief executive in February 2021.
2022Bristol-Myers Squibb
Turning Point bought as Revlimid generics arrive
BMS completed the $4.1 billion purchase of Turning Point Therapeutics in August 2022 while volume-limited generic lenalidomide began eroding Revlimid, which had peaked at $12.8 billion in 2021.
2023Bristol-Myers Squibb
Chris Boerner becomes CEO
Chris Boerner succeeded Giovanni Caforio as chief executive in November 2023 and became board chair on April 1, 2024. Weeks earlier BMS had agreed to buy Mirati, and in December it agreed to buy Karuna and RayzeBio.
2024Bristol-Myers Squibb
Karuna, Mirati and RayzeBio close; Cobenfy approved
The three deals closed between January and March 2024. On September 26, 2024 the FDA approved Cobenfy, the first schizophrenia drug that targets muscarinic rather than dopamine receptors. The Karuna charge produced an $8.9 billion net loss for 2024.
2025Bristol-Myers Squibb
BioNTech partnership, Orbital deal and $48.2B revenue
BMS agreed in June 2025 to co-develop BioNTech's bispecific BNT327 and in October 2025 to buy Orbital Therapeutics for $1.5 billion. Full-year revenue was $48.2 billion with the Growth Portfolio up 17 percent.
2025Intel
Lip-Bu Tan Becomes CEO
Lip-Bu Tan became CEO and reset the turnaround agenda around execution, cost, and focus.
2025Intel
$52.853B Revenue
Intel reported $52.853B in revenue and a $267M net loss attributable to Intel.
2025Intel
U.S. Government Takes 9.9% Stake
The U.S. government bought 433.3 million Intel shares at $20.47 for $8.9 billion, becoming the largest shareholder.
2025Intel
Nvidia Invests $5 Billion
Nvidia agreed to invest $5 billion in Intel and co-develop x86 PC and data-center products.
2025Intel
Altera Majority Sold
Intel closed the sale of 51% of Altera to Silver Lake on September 12, 2025.
2026Bristol-Myers Squibb
Guidance raised and merger reports denied
On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion after second-quarter revenue of $12.97 billion. In August, reports of AstraZeneca merger talks were followed by a senior source telling Reuters there were no discussions.
2026Intel
Q2 Revenue Up 25%
Intel reported $16.1 billion in Q2 2026 revenue, its fastest growth in more than 15 years.
Acquisitions
Bristol-Myers Squibb
- Orbital Therapeutics2025$1.5B
- Mirati Therapeutics2024$4.8B
- RayzeBio2024$4.1B
- Karuna Therapeutics2024$14B
- Turning Point Therapeutics2022$4.1B
- MyoKardia2020$13.1B
Intel
- Moovit2020$900M
- Habana Labs2019$2B
- Mobileye2017$15.3B
- Altera2015$16.7B
- McAfee2011$7.7B
Questions about Bristol-Myers Squibb vs Intel
Who is the CEO of Bristol-Myers Squibb Company and Intel Corporation?
Bristol-Myers Squibb Company is led by Christopher Boerner and Intel Corporation is led by Lip-Bu Tan. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Bristol-Myers Squibb Company founded vs Intel Corporation?
Bristol-Myers Squibb Company was founded in 1887 — 81 years before Intel Corporation, which was founded in 1968. Bristol-Myers Squibb Company's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Intel Corporation.
How many employees does Bristol-Myers Squibb Company have compared to Intel Corporation?
Bristol-Myers Squibb Company employs approximately 32,500 people, while Intel Corporation employs approximately 85,100. Intel Corporation has the larger workforce at 85,100 employees, compared to Bristol-Myers Squibb Company's 32,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Bristol-Myers Squibb Company and Intel Corporation headquartered?
Both Bristol-Myers Squibb Company and Intel Corporation are headquartered in United States, meaning they operate under the same primary regulatory and tax environment.
Who founded Bristol-Myers Squibb Company and Intel Corporation?
Bristol-Myers Squibb Company was founded by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers. Intel Corporation was founded by Robert Noyce, Gordon Moore.
Which company has a longer operating history — Bristol-Myers Squibb Company or Intel Corporation?
Bristol-Myers Squibb Company has been operating for approximately 139 years, making it the more established of the two companies. Intel Corporation has been in operation for around 58 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Bristol-Myers Squibb vs Intel overview